Compare 3M Company (MMM) vs Novavax Inc (NVAX) Price & Performance

MMM trades at $167.52, down 0.62% on the day, with a bearish technical signal but strong fundamentals including a net income margin of 11.9% and consistent earnings beats. Recent news highlights strength in transportation and electronics segments, though consumer demand remains soft. The stock has gained 9.1% over the past year, supported by industrial momentum and cost management initiatives.

Outlook is mixed: analyst consensus is a Buy with a $173 price target, but high debt and valuation ratios pose risks. Near-term catalysts include Q3 2026 earnings and continued segment growth, while headwinds include cost pressures and weak consumer sales. The dividend of $0.78 per share provides income support.

Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.

The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.